Invention Application
- Patent Title: ENHANCED OLIGONUCLEOTIDES FOR INHIBITING RTEL1 EXPRESSION
-
Application No.: US17590754Application Date: 2022-02-01
-
Publication No.: US20220251556A1Publication Date: 2022-08-11
- Inventor: Erik FUNDER , Natascha HRUSCHKA , Susanne KAMMLER , Erich KOLLER , Brian LEONARD , Souphalone LUANGSAY , Susanne MOHR , Tobias NILSSON , Søren OTTOSEN , Lykke PEDERSEN , Søren V. RASMUSSEN , Steffen SCHMIDT , Sabine SEWING , Daniel TURLEY , Johanna Marie WALTHER
- Applicant: HOFFMANN-LA ROCHE INC.
- Applicant Address: US NJ Little Falls
- Assignee: HOFFMANN-LA ROCHE INC.
- Current Assignee: HOFFMANN-LA ROCHE INC.
- Current Assignee Address: US NJ Little Falls
- Priority: EP21154701.3 20210202,EP21207002.3 20211108
- Main IPC: C12N15/113
- IPC: C12N15/113 ; A61K31/7088 ; A61P31/20
Abstract:
Enhanced antisense oligonucleotides targeting Regulator of telomere elongation helicase 1 (RTEL1), leading to modulation of the expression of RTEL1 or modulation of RTEL1 activity are provided. This disclosure relates to the use of enhanced antisense oligonucleotides targeting RTEL1 for use in treating and/or preventing a hepatitis B virus (HBV) infection, in particular a chronic HBV infection. This disclosure further relates to the use of the enhanced antisense oligonucleotides targeting RTEL1 for destabilizing cccDNA, such as HBV cccDNA. A pharmaceutical composition and its use in the treatment and/or prevention of a HBV infection is also described.
Public/Granted literature
- US11898145B2 Enhanced oligonucleotides for inhibiting RTEL1 expression Public/Granted day:2024-02-13
Information query
IPC分类:
